ViroGates A/S : announces its third clinical routine customer in Spain

13.8.2020 19:10:43 CEST | ViroGates | Company Announcement

COMPANY ANNOUNCEMENT                                                                            13 August 2020

No. 20-2020

BIRKERØD, DENMARK - ViroGates A/S, a medical technology company developing blood tests for better triaging in hospitals to improve patient care and reduce healthcare costs, today announces that Hospital Clínico Universitario Virgen de la Arrixaca located in the Murcia region in Spain has started to use suPARnostic® TurbiLatex on its Roche cobas platform to help the process of triage in the emergency department with a focus on triage in relation to COVID-19 disease.

This is the second hospital in the Murcia region and the third Spanish hospital this year that has adopted the suPARnostic® TurbiLatex product in clinical routine use.

The Arrixaca University Hospital is the biggest hospital in the Murcia region with around 1200 beds and an uptake population of around 1.4 million people. As the Murcia region, like the rest of Spain is very affected by COVID-19 disease, the hospital is handling around 60 patients per day with COVID-19 disease and with a surge in the trend

The implementation has been led by Dr. Dr. Jose Antonio Noguera Velasco, head of the laboratory and his team.

Dr. Noguera says in a comment:"Given the previous studies, we have high expectations that the measurement of suPAR will help us in stratification, and therefore in improving the care of our patients, especially in the current circumstances in which the CoVID-19 pandemic seriously compromises our healthcare system."

Jakob Knudsen, Chief Executive Officer of ViroGates, says:”We are excited to work with the biggest hospital in the Murcia region and happy that the doctors at the hospital appreciated the data created at other hospitals in Spain – particularly the hospital in Cartagena being part of the same region. We are convinced that the implementation will be of high value in the triage of patients both in this very challenging Corona virus setting and beyond.”

The announcement can be found at https://www.virogates.com/investor/announcements 

For further information please contact:

ViroGates A/S:

CEO, Jakob Knudsen

Tel. [phone], email: [e-mail]

Certified Advisor:

Västra Hamnen Corporate Finance

Per Lönn

Tel. [phone], email: [e-mail]

About ViroGates

ViroGates A/S is an international medical technology company developing and marketing blood test products under the suPARnostic® brand for better triaging in hospitals to improve patient care, reduce healthcare costs and empower clinical staff.

The company was founded in 2000 based on the discovery that suPAR was predictive of outcome in HIV-infections and subsequently in many other disease areas. Headquartered in Denmark, ViroGates’ sales force covers the Nordics, Spain, and France, while distributors serve other markets.

ViroGates’ shares (VIRO) are listed on Nasdaq First North Growth Market Denmark. For more information, please visit www.virogates.com.

About suPAR and suPARnostic®

suPAR is the biomarker detected by ViroGates’ suPARnostic® products and is a protein in plasma, measurable in every human being. suPAR is considered a general risk status biomarker indicating disease presence, disease severity and progression, organ damage and mortality risk across disease areas such as cardiovascular diseases, kidney diseases, type 2 diabetes, cancer, etc. Strong scientific evidence from more than 600 clinical trials and studies show that the higher the level of suPAR, the worse the prognosis for the patient.

The suPARnostic® products can be used to support healthcare professionals in making clinical decisions on hospitalization or discharge of acute care patients. The increasing demands on health systems globally and tightening healthcare budgets necessitate efficiency improvements and innovative solutions in hospitals. The use of suPAR in clinical routine in emergency departments can improve patient care and reduce healthcare costs by increasing the number of discharges by 34% and reducing the average hospital length-of-stay by 6% without affecting mortality. suPARnostic® TurbiLatex is currently available on Roche Diagnostics’ cobas,  instruments, Siemens ADVIA XPT instruments and the Abbott Labs Architect instruments. ViroGates works with partners to develop solutions for other platforms.

Disclaimer

Prospects about the future reflect ViroGates' current expectations for future events and results. The statements are by nature inherent in risks, uncertainties and other matters that are difficult to predict or out of control. The actual results may therefore differ from the expectations expressed.

Contacts

• Jakob Knudsen, CEO, [phone], [e-mail]

Attachments

• 20200813-ViroGates Company announcement 20.pdf

© Ritzau Denmark, source Ritzau English Regulatory Releases